Contact Information

Currently Enrolling Trials

General Information

Ceftin (Cefuroxime axetil) has been approved by the U.S. Food and Drug Administration for the treatment of secondary bacterial infections of acute bronchitis with 5-day therapy.

Approval Date: 1997-09-01

Company Name: GlaxoSmithKline

Back to Listings

13Jul
Decentralized Clinical Trials: Benefits of a Better Patient Experience
22Jul
The Biden Administration’s FDA: The First Six Months and What to Expect for the Rest of the Year
28Sep
4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit
18Oct
MAGI's Clinical Research vConference — Fall 2021

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here

Ceftin (cefuroxime axetil)

Profile

Contact Information

Currently Enrolling Trials

General Information

Upcoming Events

Decentralized Clinical Trials: Benefits of a Better Patient Experience

The Biden Administration’s FDA: The First Six Months and What to Expect for the Rest of the Year

4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit

MAGI's Clinical Research vConference — Fall 2021

Featured Products

Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

Stop Over-Reporting Adverse Events, FDA Officials Tell Sponsors

Ask the Experts: FDA Advice on Protocol Deviations

‘Snapback’ to Pre-Pandemic Trial Approaches Unlikely, Focus Is on Innovation

Despite Pandemic Positives, Crisis Highlights Issues with Growing Use of Service Providers

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.